Background: Angiographic and clinical outcomes associated with zotarolimus-eluting stent have been well characterized in a variety of studies. This study is to evaluate the safety and efficacy of the Endeavor zotarolimus-eluting stent (ZES) in Korean patients with coronary artery disease after 5-year clinical follow-up in the Endeavor Ansan Registry. Methods; This is a single center, single-arm, observational study; from July 2006 to December 2006, 105 patients in whom Endeavor��� stent was deployed for de novo coronary artery stenoses according to a standardized procedures, were enrolled. The primary end points was major adverse cardiac events (MACE) defined as death, myocardial infarction(MI), emergent cardiac surgery, or repeat revascularization of the target lesion (TLR), in hospital, at 9 months, 1, 3, and 5 years. The secondary end points was occurrence of stent thrombosis. Results; The mean age was 61짹11.3 years , 70 male(66.7%), 43 diabetes(41.0%) and 33 MI(31.4%)patients were enrolled. Total 167 ZES were implanted. The average reference vessel diameter was 2.87짹0.45mm, and the mean lesion length was 25.0짹5.36mm. Clinical follow-up after 5 year was accomplished for 66 patients(62.9%). The in-hospital MACE was 1.9% (2 cardiac death). The incidence of MACE at 9 months was 6.7% (7 of 105). At 9 months, overall rate of TLR was 4.76% (5 of 105). The incidence of MACE at 1,3,5 year were 1.3%, 8.3%, and 6.1%. There were one case of subacute stent thrombosis(0.9%) and no late or very late stent tnrombosis. Conclusion; These findings demonstrate that the Endeavor��� stent in Korean patients is associated with low rates of MACE and stent thrombosis after 5 years of clinical follow up. Further study in a larger patient cohort and for a longer duration is warranted.